Tasly Pharmaceutical Group (600535.SH) announced that recently its wholly-owned subsidiary Jiangsu Tasly Emperor Yi Pharmaceutical Co., Ltd. ("Jiangsu Emperor Yi") has received the supplementary drug application approval notice for Furmatting Ketotifen Tablets issued by the National Medical Products Administration. The drug is approved through the consistency evaluation of generic drug quality and efficacy. As of now, Jiangsu Emperor Yi's cumulative R&D investment in the consistency evaluation of this drug is RMB 5.4924 million. Furmatting Ketotifen Tablets are used for allergic rhinitis and allergic asthma, and are a Class B drug in the "National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalogue (2023)." According to data from Minenet, the sales of Furmatting Ketotifen Tablets in public hospitals in urban and county areas and urban entity pharmacies in China amounted to RMB 66.92 million in 2023.
Tasly Pharmaceutical Group (600535.SH) announced that recently its wholly-owned subsidiary Jiangsu Tasly Emperor Yi Pharmaceutical Co., Ltd. ("Jiangsu Emperor Yi") has received the supplementary drug application approval notice for Furmatting Ketotifen Tablets issued by the National Medical Products Administration. The drug is approved through the consistency evaluation of generic drug quality and efficacy.
Furmatting Ketotifen Tablets are used for allergic rhinitis and allergic asthma, and are a Class B drug in the "National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalogue (2023)." As of now, Jiangsu Emperor Yi's cumulative R&D investment in the consistency evaluation of this drug is RMB 5.4924 million. According to data from Minenet, the sales of Furmatting Ketotifen Tablets in public hospitals in urban and county areas and urban entity pharmacies in China amounted to RMB 66.92 million in 2023.